Alliance Wealth Advisors (Utah)’s Amneal Pharmaceuticals AMRX Stock Holding History

Alliance Wealth Advisors (Utah)’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$233K	Buy	+13,439	New	+$184K	0.04%	219

Other funds holding AMRX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Alliance Wealth Advisors (Utah)'s AMRX Position: Q2 2026 in Review

Alliance Wealth Advisors (Utah) opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 13,439 shares worth $233K. The stake represents 0.04% of the portfolio and ranks #219 among its holdings.

47 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Alliance Wealth Advisors (Utah) held 13,439 shares of Amneal Pharmaceuticals worth $233K as of Q2 2026.
Amneal Pharmaceuticals was a new Alliance Wealth Advisors (Utah) position in Q2 2026.
Amneal Pharmaceuticals made up 0.04% of Alliance Wealth Advisors (Utah)'s portfolio in Q2 2026, its #219 holding.
47 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Alliance Wealth Advisors (Utah)'s 13F filing for Q2 2026, filed 23 Jul 2026.